These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3132216)

  • 1. Oral iron chelating drugs: coming but not yet ready for clinical use.
    Hershko C
    Br Med J (Clin Res Ed); 1988 Apr; 296(6629):1081-2. PubMed ID: 3132216
    [No Abstract]   [Full Text] [Related]  

  • 2. An oral treatment for iron overload in thalassemia?
    Kowdley KV; Tavill AS
    Hepatology; 1996 Feb; 23(2):380-2. PubMed ID: 8591869
    [No Abstract]   [Full Text] [Related]  

  • 3. Combining two orally active iron chelators for thalassemia.
    Berdoukas V; Carson S; Nord A; Dongelyan A; Gavin S; Hofstra TC; Wood JC; Coates T
    Ann Hematol; 2010 Nov; 89(11):1177-8. PubMed ID: 20217085
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases. Part 1. Taichung, Taiwan. April 22-26, 2005.
    Hemoglobin; 2006; 30(1):63-137. PubMed ID: 16764044
    [No Abstract]   [Full Text] [Related]  

  • 5. Deferiprone for thalassaemia.
    Pippard MJ; Weatherall DJ
    Lancet; 2000 Oct; 356(9239):1444-5. PubMed ID: 11052617
    [No Abstract]   [Full Text] [Related]  

  • 6. Report on the proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
    Peng CT; Fucharoen S; Kontoghiorghes GJ; Tsai CH
    Hemoglobin; 2006; 30(1):63-8. PubMed ID: 16540418
    [No Abstract]   [Full Text] [Related]  

  • 7. Deferasirox in thalassemia patients with end-stage renal disease.
    Beydoun HG; Saliba AN; Taher AT
    Am J Hematol; 2016 Oct; 91(10):E456-7. PubMed ID: 27342388
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron chelating drugs.
    Kontoghiorghes GJ
    Br Med J (Clin Res Ed); 1988 Jun; 296(6637):1672-3. PubMed ID: 3135073
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Patient compliance in iron-chelating therapy of beta-thalassemia major].
    Di Gregorio F; Romeo MA; Tasca R; Passaniti G
    Minerva Pediatr; 1983 May; 35(10):489-93. PubMed ID: 6877194
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron chelation therapy: the need for orally active drugs.
    Hoffbrand AV
    J Lab Clin Med; 1998 Apr; 131(4):290-1. PubMed ID: 9579378
    [No Abstract]   [Full Text] [Related]  

  • 12. [New therapeutic trends in thalassemia: oral chelating agents].
    Carnelli V; Terzoli S; Fossati G; Careddu G; Perri M; Pedrotti L; Mirra N
    Pediatr Med Chir; 1992; 14(3):273-5. PubMed ID: 1528794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An orally active iron chelator.
    Nathan DG
    N Engl J Med; 1995 Apr; 332(14):953-4. PubMed ID: 7877655
    [No Abstract]   [Full Text] [Related]  

  • 14. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy for patients with myelodysplastic syndrome.
    Yeh SP; Yang YS; Yao CY; Peng CT
    Hemoglobin; 2009; 33(5):339-45. PubMed ID: 19814680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1).
    Rombos Y; Tzanetea R; Konstantopoulos K; Simitzis S; Zervas C; Kyriaki P; Kavouklis M; Aessopos A; Sakellaropoulos N; Karagiorga M; Kalotychou V; Loukopoulos D
    Haematologica; 2000 Feb; 85(2):115-7. PubMed ID: 10681716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): a status quo.
    Taher AT; Musallam KM; Viprakasit V; Porter JB; Cappellini MD
    Blood Cells Mol Dis; 2014; 52(2-3):88-90. PubMed ID: 24041597
    [No Abstract]   [Full Text] [Related]  

  • 18. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review.
    Evangeli M; Mughal K; Porter JB
    Hemoglobin; 2010 Jun; 34(3):305-21. PubMed ID: 20524820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K; Sivaramakrishnan G
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.